John Nguyen

John Nguyen

Auto-generated profile, based on publicly available information

John Nguyen

Sino-American Cancer Foundation (SACF), Covina, California

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MLMelissa Lever
Melissa Lever
HLHong-Sheng Lim
Hong-Sheng Lim
PKPhilipp Kruger
Philipp Kruger
JNJohn Nguyen
John Nguyen
NTNicola Trendel
Nicola Trendel
ODOmer Dushek
Omer Dushek
Significance: T cells initiate and regulate adaptive immune responses when their T-cell antigen receptors recognize antigens. The T-cell response is known to depend on the antigen affinity/dose, but the precise relationship, and the mechanisms underlying it, are debated. To resolve the debate, we stimulated T cells with antigens spanning a 1 million-fold range in affinity/dose. We found that a different antigen (and hence different affinity) produced the largest T-cell response at different doses. Using model identification algorithms, we report a simple mechanistic model that can predict the T-cell response from the physiological low-affinity regime into the high-affinity regime applicable to therapeutic receptors.

19 January 2021 in Science Signaling
Verified
Journal Article
Closed access
NTNicola Trendel
Nicola Trendel
PKPhilipp Kruger
Philipp Kruger
SGStephanie Gaglione
Stephanie Gaglione
JNJohn Nguyen
John Nguyen
JPJohannes Pettmann
Johannes Pettmann
ODOmer Dushek
Omer Dushek
Reduced T cell responses by contrast antigen stimulation can be rescued by signals from costimulatory receptors.

15 September 2020 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
Enas Abu-ShahEnas Abu-Shah
Enas Abu-Shah
NTNicola Trendel
Nicola Trendel
PKPhilipp Kruger
Philipp Kruger
JNJohn Nguyen
John Nguyen
JPJohannes Pettmann
Johannes Pettmann
ODOmer Dushek
Omer Dushek
T cells recognizing cognate pMHC Ags become activated to elicit a myriad of cellular responses, such as target cell killing and the secretion of different cytokines, that collectively contribute to adaptive immunity. These effector responses have been hypothesized to exhibit different Ag dose and affinity thresholds, suggesting that pathogen-specific information may be encoded within the nature of the Ag. In this study, using systematic experiments in a reductionist system, in which primary human CD8+ T cell blasts are stimulated by recombinant peptides presented on MHC Ag alone, we show that different inflammatory cytokines have comparable Ag dose thresholds across a 25,000-fold variation in affinity. Although costimulation by CD28, CD2, and CD27 increased cytokine production in this system, the Ag threshold remained comparable across different cytokines. When using primary human memory CD8+ T cells responding to autologous APCs, equivalent thresholds were also observed for different cytokines and killing. These findings imply a simple phenotypic model of TCR signaling in which multiple T cell responses share a common rate-limiting threshold and a conceptually simple model of CD8+ T cell Ag recognition, in which Ag dose and affinity do not provide any additional response-specific information. Key Points CD8+ T cells produce TNF-α, IL-2, and IFN-γ with similar Ag thresholds. Costimulation decreases Ag thresholds similarly for different cytokines. A common rate-limiting switch downstream of the TCR can explain these findings.

1 March 2026 in Cancer Research Communications
Verified
Journal Article
Open access
CTChakrapani Tripathi
Chakrapani Tripathi
SZSergey Zolov
Sergey Zolov
JNJohn Nguyen
John Nguyen
FLFrank Luh
Frank Luh
VNVenkatesh Natarajan
Venkatesh Natarajan
YYYun Yen
Yun Yen
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the rapid expansion of undifferentiated myeloid progenitors, leading to impaired hematopoiesis and poor patient prognosis. Although chimeric antigen receptor (CAR) T-cell therapy using single-chain variable fragments has revolutionized immunotherapy, clinical application in AML remains limited by on-target, off-tumor toxicities, largely due to shared antigen expression on normal hematopoietic stem and progenitor cells. To address this challenge, we developed a nanobody-based CAR T-cell platform directed against C-type lectin-like molecule-1 (CLL-1), a myeloid-restricted surface antigen minimally expressed on healthy hematopoietic stem cells but consistently enriched on AML blasts and leukemic stem cells. Leveraging the high specificity, solubility, and reduced immunogenicity of llama-derived single-domain variable heavy-chain antibodies, we engineered both CLL-1 and CD33 nanobody CAR constructs and systematically compared their functional activity. Functional validation included real-time cytotoxicity monitoring using IncuCyte imaging of mKate2-labeled AML cells, serial tumor rechallenge assays to assess sustained killing, and NOD/SCID/IL2Rγnull xenograft models to evaluate in vivo efficacy under conditions of high leukemic burden. CLL-1 and CD33 CAR T cells demonstrated rapid and durable cytotoxicity, with significant killing efficiency at low effector-to-target ratios (0.33:1). Unlike CD33 CAR T cells, CLL-1–directed CARs spared normal hematopoietic progenitors, preserving colony-forming capacity. Importantly, CLL-1 CAR T cells retained a favorable memory phenotype with stable proliferation and viability, whereas cytokine release assays confirmed effective yet antigen-specific immune activation. In vivo, treatment with CLL-1 CAR T cells resulted in profound and sustained tumor regression in AML xenografts, accompanied by the persistence of functional CAR T cells. Together, these findings establish CLL-1–targeted nanobody-based CAR T cells as a precision-engineered immunotherapy with potent antileukemic activity, reduced off-target toxicity, and enhanced translational potential. This platform provides a promising therapeutic avenue to overcome current barriers in AML CAR T-cell development and improve patient outcomes. Significance: Nanobody-based CLL-1 CAR T-cell therapy balances potent antitumor activity with hematopoietic preservation, highlighting the potential of our CLL-1 CAR T-cell platform as a next-generation, safer, and clinically superior strategy for effective AML treatment.

11 March 2026
Verified
Other
Open access
CTChakrapani Tripathi
Chakrapani Tripathi
SZSergey Zolov
Sergey Zolov
JNJohn Nguyen
John Nguyen
FLFrank Luh
Frank Luh
VNVenkatesh Natarajan
Venkatesh Natarajan
YYYun Yen
Yun Yen
Figure S8. Nanobody-based CAR T cells represent an effective and compact alternative to scFv-based CAR constructs

11 March 2026
Verified
Other
Open access
CTChakrapani Tripathi
Chakrapani Tripathi
SZSergey Zolov
Sergey Zolov
JNJohn Nguyen
John Nguyen
FLFrank Luh
Frank Luh
VNVenkatesh Natarajan
Venkatesh Natarajan
YYYun Yen
Yun Yen
Figure S5. CD33 nanobodies clones screening in Human T cells